07/19/2005 1:15:53 PM ET


    SWISS MEDICA WELCOMES EXPERIENCED HEALTH INDUSTRY PROFESSIONAL CHARLES ORR TO BOARD
    OF DIRECTORS
      
    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB: SWME
    July 19, 2005

    SWISS MEDICA WELCOMES EXPERIENCED HEALTH INDUSTRY PROFESSIONAL CHARLES ORR TO BOARD
    OF DIRECTORS

    Toronto, Ontario Canada – Swiss Medica Inc. (OTC BB: SWME) today announced the appointment of Charles
    Orr to its Board of Directors. Mr. Orr was President and CEO of Shaklee Corporation from 1993 to 2000, where
    sales grew to $700 million annually. Mr. Orr currently serves on the Board of Directors of Herbalife (NYSE: HLF),
    a leading global healthcare network marketing company, the Direct Selling Education Foundation, and is an
    advisor to several private companies.

    Prior to his work with Shaklee, Mr. Orr held senior management and board of director positions in a variety of life
    insurance, financial services and technology enterprises including Federated Investors, Continental Insurance,
    Southwestern Life Insurance Company, Connecticut General Insurance Corporation, Xerox and RCA.

    “We are delighted to have someone of Charlie’s caliber, experience and depth to join the Swiss Medica Board of
    Directors,” said Raghu Kilambi, CEO of Swiss Medica. “Not only does he have 40 years of business experience
    and a keen knowledge of how to grow a business based on providing effective, scientifically-proven health
    solutions, but he has also taken the time to get to know our business throughout the last 18 months as chairman
    of our Board of Advisors. We look forward to enjoying his continued and valued contribution to Swiss Medica in
    his new role.”

    Mr. Orr said he has learned a great deal from working with Swiss Medica. “Swiss Medica is developing clinically
    proven, patented technologies that address chronic ailments – and provide, safe alternatives to prescription
    products,” he said. “This is a very innovative company. I look forward to being able to make a greater
    contribution to Swiss Medica as it builds a loyal consumer base and sustained success.”

    About Swiss Medica Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a
    world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

    Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
    relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
    healthcare professionals in the United States, Canada and in Europe. O24™ is widely available throughout
    Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of
    pharmacies throughout the United States. Customers can also visit www.O24zone.com, for ordering details and
    store locators for the nearest pharmacy.

    Swiss Medica also manufactures PMS Escape® which holds US Patent #’s 5760014 and 5612320. PMS
    Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
    changes in mood and appetite that women experience during the premenstrual period. Customers can also visit
    www.pmsescape.com for additional information and ordering details.

    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United
    States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    For more information, please contact:

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    djones@swissmedica.com